George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCPT.L Regulatory News (CPT)

  • There is currently no data for CPT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First Sales Order China and Trading Update

13 Jun 2017 07:00

RNS Number : 8738H
Concepta PLC
13 June 2017
 

 

13 June 2017

Concepta plc ("Concepta" or the "Company")

First £225,000 Sales Order for myLotus Fertility Products Signed in China and Trading Update

Concepta Plc (AIM: CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*, announces that it has received its first sales order for RMB 1.95million (£225,000 at today's exchange rate of RMB 8.33: £1) for its myLotus fertility products from its partner in China, HuanZhong Biotech Co.Ltd ('HZ Biotech'). 

This sales order represents the first purchase for the Company's myLotus products and will see HZ Biotech distribute myLotus products in China to help achieve market penetration for the initial launch of the product in the country. The Board anticipates that further sales orders will be made by HZ Biotech in line with its partner agreement and will update the market on these developments accordingly.

Concepta's myLotus product is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

 

Notwithstanding the significant progress made to date by Concepta on achieving its first sales and market penetration into China, as shareholders will be aware, the Company's original business plan envisaged commencement of sales during the first quarter of 2017. Given the receipt of the above order, the Board has re-appraised its sales forecast for 2017, and now believes turnover for year ending 2017 will be below market expectations. However, as the Company has delayed costs and initiated tight cost control, this will result in the losses for the year being broadly in line with current market expectations.

Erik Henau, CEO commented: "This is a positive and significant milestone for Concepta and is the result of close co-operation with our Chinese partners, who have helped us refine our market entry strategies into China. Through our office in Shanghai we continue to develop close local relationships that allow us to actively manage the profile and development of the myLotus brand. This first order allows us to test our three identified routes to market (IVF clinics, direct to consumer and hospitals) and we expect to make further announcements in the future as we look to expand our distribution network in China.

"We are now in a position to activate the whole supply chain, leveraging core UK elements configured to provide a scalable international supply chain. This is the result of a significant investment in regulatory processes and physical assets enabling our modular systems to expand capacity in line with demand."

Chairman Adam Reynolds commented; "It is a significant undertaking to transform a start-up situation with a pioneering product in development to one where all the infrastructure is maturing and initial distribution channels and sales have been established for a new product in an overseas territory. We are pleased that we have transitioned the Company to that position, although as outlined above, we have experienced some delays to our hospital trials schedule that will impact revenue this calendar year. Nonetheless, Concepta has made significant progress since coming to market, and the infrastructure and relationships we now have in place provide an excellent platform for growth."

Enquiries:

 

Concepta plc

Adam Reynolds, Chairman

Tel: +44 (0) 7785 908158

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

 

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles / Joe Burgess / Francesca Hillier

Tel: +44 (0) 7748 843 871

 

 

About Concepta Plc:

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

 

Founded in 2013, Concepta has developed a revolutionary flagship product 'myLotus' for home self-testing that helps women with unexplained infertility to conceive.

 

myLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

 

Concepta has a defined route to market for its new 'myLotus' product with Regulatory approvals for launch in China in place for H1 2017 and CE-Marking for UK and Europe to follow later in 2017. The revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDLLFSTRRIFLID
Date   Source Headline
2nd Dec 20204:25 pmRNSChange of name to MyHealthChecked Plc
2nd Dec 202011:06 amRNSSecond Price Monitoring Extn
2nd Dec 202011:01 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name
24th Nov 20204:41 pmRNSSecond Price Monitoring Extn
24th Nov 20204:36 pmRNSPrice Monitoring Extension
23rd Nov 20207:00 amRNSAcquisition of home-use genetic testing company
28th Sep 20207:00 amRNSHalf-year Report
22nd Jul 20207:00 amRNSChange of Adviser
6th Jul 20207:00 amRNSCommercial update; Change of registered office
2nd Jul 20203:24 pmRNSResult of AGM
5th Jun 20207:01 amRNSDirector/PDMR Shareholding
5th Jun 20207:00 amRNSNotice of Annual General Meeting
2nd Jun 20207:00 amRNSCommercial update
29th May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSPartnership agreement with Abingdon Health
27th Apr 20208:16 amRNSDirector/PDMR Shareholding
24th Apr 202011:26 amRNSResult of GM & Completion of Fundraise
14th Apr 20209:27 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSManufacturing outsourcing agreements for myLotus®
8th Apr 20207:00 amRNSPlacing and Subscription to raise £1.9 million
29th Jan 20207:00 amRNSTrading Update
14th Nov 20197:00 amRNSBoard Appointments
13th Nov 20198:35 amRNSBoard changes - replacement
13th Nov 20197:00 amRNSBoard Changes
31st Oct 20197:00 amRNSConcepta announces first myLotus® UK birth
25th Oct 20197:00 amRNSBoard Changes
30th Sep 20197:00 amRNSFirst myLotus® UK Fertility Clinic collaboration
30th Sep 20197:00 amRNSInterim Results
29th Jul 20197:00 amRNSGrant of Options
9th Jul 20197:00 amRNSmyLotus® pregnancies in double figures
13th Jun 20192:01 pmRNSResult of AGM
21st May 20199:00 amRNSNotice of AGM
14th May 20197:01 amRNSAnnual Results
14th May 20197:00 amRNSConcepta announces first myLotus® pregnancies
30th Apr 20194:28 pmRNSHolding(s) in Company
30th Apr 20191:46 pmRNSTR-1: form for notification of major holdings
29th Apr 20191:20 pmRNSTR-1: notification of major holdings
26th Apr 201910:52 amRNSDirector/PDMR Shareholding
8th Apr 20197:00 amRNSPlacing to raise £2.3m; Notice of General Meeting
29th Mar 20197:00 amRNSConcepta to supply myLotus® to Boots UK
12th Mar 20197:00 amRNSConcepta to supply myLotus® to Walgreens Boots
17th Dec 20187:00 amRNSmyLotus® successful UK launch
31st Oct 20187:00 amRNSmyLotus® launch at The Fertility Show, London
29th Oct 20187:00 amRNSmyLotus gains CE-mark regulatory approval
5th Oct 20182:42 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSGrant of Options
27th Sep 20184:41 pmRNSSecond Price Monitoring Extn
27th Sep 20184:37 pmRNSPrice Monitoring Extension
27th Sep 20187:01 amRNSDirectorate change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.